Revolution Medicines Q4 2024 net loss $194.6M, cash $2.3B; Phase 3 PDAC enrollment target 2025

Revolution Medicines, Inc.

2024-FY EPS reported -$3.58

Q4 net loss $194.6M vs $161.5M YoY; full year net loss $600.1M vs $436.4M.
Cash and securities $2.3B at Dec 31, 2024, up from $1.9B; $823M net raised in Dec 2024 public offering.
2025 GAAP net loss guidance $840M-$900M; cash runway expected into H2 2027.
Expects to complete enrollment in Phase 3 RASolute 302 (PDAC) in 2025 for data readout in 2026; Phase 3 RASolve 301 (NSCLC) now activating sites.
Plans to initiate two additional registrational trials for daraxonrasib in earlier-line PDAC in H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.